PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28234053
OWN - NLM
STAT- MEDLINE
DA  - 20170224
DCOM- 20170306
LR  - 20170306
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 38
IP  - 2
DP  - 2017 Mar 01
TI  - A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly 
      controlled asthma.
PG  - 157-164
LID - 10.2500/aap.2017.38.4034 [doi]
AB  - BACKGROUND: Asthma is characterized by a complex interaction of inflammatory
      mediators. The prostaglandin D2 receptor, chemoattractant receptor-homologous
      molecule on Th2 cells (CRTH2), plays a pivotal role in the pathogenesis of
      allergic airway inflammation. OBJECTIVE: To ealuate the efficacy, safety, and
      pharmacokinetics of BI 671800, a CRTH2 antagonist, when added to inhaled
      corticosteroid therapy in adult patients with symptomatic asthma. METHODS: In
      this phase IIa, 12-week, randomized, double-blind, three-period, four-treatment, 
      incomplete block crossover trial, BI 671800 was administered either as a single
      400-mg dose in the morning (A.M.) or evening (P.M.), or 200 mg twice daily (A.M. 
      and P.M.) versus placebo, together with fluticasone propionate (44 mug, two
      inhalations twice daily). The primary end point was the change from baseline in
      trough forced expiratory volume in 1 second percentage predicted after 4 weeks.
      The secondary end point was the change in Asthma Control Questionnaire score from
      baseline. RESULTS: A total of 108 patients were randomized and treated. After 4
      weeks, the adjusted mean (+/- SE) treatment differences for the primary end point
      versus placebo were 0.08 +/- 0.62%, 0.28 +/- 0.61%, and 0.67 +/- 0.63% for BI
      671800 at 200 mg twice daily, 400 mg A.M., and 400 mg P.M., respectively (not
      statistically significant). No statistically significant or clinically meaningful
      differences in the Asthma Control Questionnaire score were observed versus
      placebo. Each treatment was well tolerated. CONCLUSION: BI 671800 at a dose of
      400 mg administered for 4 weeks with fluticasone propionate did not provide
      clinical improvement in patients with asthma; reasons for this are unclear, but
      it may be due to insufficient inhibition of the CRTH2 receptor at the doses used.
FAU - Miller, David
AU  - Miller D
FAU - Wood, Chester
AU  - Wood C
FAU - Bateman, Eric
AU  - Bateman E
FAU - LaForce, Craig
AU  - LaForce C
FAU - Blatchford, Jon
AU  - Blatchford J
FAU - Hilbert, James
AU  - Hilbert J
FAU - Gupta, Abhya
AU  - Gupta A
FAU - Fowler, Andrew
AU  - Fowler A
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (BI 671800)
RN  - 0 (Benzamides)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (prostaglandin D2 receptor)
RN  - CUT2W21N7U (Fluticasone)
SB  - IM
MH  - Adult
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Asthma/*drug therapy/physiopathology
MH  - Benzamides/*therapeutic use
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluticasone/therapeutic use
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrimidines/*therapeutic use
MH  - Receptors, Immunologic/*antagonists & inhibitors
MH  - Receptors, Prostaglandin/*antagonists & inhibitors
MH  - Treatment Outcome
MH  - Vital Capacity
EDAT- 2017/02/25 06:00
MHDA- 2017/03/07 06:00
CRDT- 2017/02/25 06:00
AID - 10.2500/aap.2017.38.4034 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2017 Mar 1;38(2):157-164. doi: 10.2500/aap.2017.38.4034.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>